https://clinicaltrials.gov/ct2/show/NCT04989335?term=zantrene&draw=2&rank=2
Noting that inclusion requirement for Sheba 2.0 is "Cardiac ejection fraction ≥50%, assessed by 2-Dimensional echocardiogram."
Will this also be assessed post dosing?
Ann: Expanded Heart Protection Discovery for Zantrene, page-231
-
- There are more pages in this discussion • 156 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.56 |
Change
0.010(0.65%) |
Mkt cap ! $269.1M | |||
| Open | High | Low | Value | Volume |
| $1.55 | $1.59 | $1.53 | $99.70K | 63.97K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 283 | $1.56 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 2000 | 1 |
View Market Depth
| Last trade - 15.56pm 01/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |